Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VRC H1ssF-3928 mRNA-LNP Vaccine in Healthy Adults
NCT05755620Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of H1ssF in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of adverse events of special interest (AESIs) corresponding to myocarditis, pericarditis, or myopericarditis, Occurrence of any adverse events of special interest (AESIs) and 7 more. Started Apr 2023; status: completed.
02
Drugs
H1ssF
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05755620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755620.